Literature DB >> 18662131

Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus.

Scott M Ward1, Prabhjeet Phalora, Daniel Bradshaw, Heike Leyendeckers, Paul Klenerman.   

Abstract

BACKGROUND: The frequency of protective antiviral memory B cells after hepatitis B virus (HBV) vaccination is unknown.
METHODS: A novel 2-step immunomagnetic protocol to assess the ex vivo frequency of protective HBV surface antigen (HBsAg)-specific memory B cells was used.
RESULTS: HBsAg-specific memory B cells were detected in vaccinated individuals, although at very low frequency (median, 0.2% of CD19(+) cells [range, 0%-4% of CD19(+) cells]). No correlation existed between the frequency of HBsAg-specific memory B cells and the corresponding serum antibody titer or B cell enzyme-linked immunosorbent spot findings.
CONCLUSION: Our results indicate sustained B cell-mediated protection against HBV despite waning antibody titers, which is consistent with clinical observations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18662131     DOI: 10.1086/591094

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Memory T cells specific for HBV enumerated by a peptide-based cultured enzyme-linked immunospot assay in healthy HBV-vaccinated subjects.

Authors:  Irene Cassaniti; Sandra A Calarota; Kodjo M G Adzasehoun; Antonella Chiesa; Giuditta Comolli; Maurizio Parea; Fausto Baldanti
Journal:  Hum Vaccin Immunother       Date:  2016-07-08       Impact factor: 3.452

2.  Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine.

Authors:  Ali Rowhani-Rahbar; Frances B Alvarez; Janine T Bryan; James P Hughes; Stephen E Hawes; Noel S Weiss; Laura A Koutsky
Journal:  J Clin Virol       Date:  2011-12-30       Impact factor: 3.168

3.  Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus.

Authors:  Haruki Komatsu; Ayano Inui; Tsuyoshi Sogo; Eitaro Hiejima; Akihiko Tateno; Paul Klenerman; Tomoo Fujisawa
Journal:  BMC Infect Dis       Date:  2010-04-28       Impact factor: 3.090

4.  Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinoma.

Authors:  Qun-Xiong Pan; Zi-Jian Su; Jian-Hua Zhang; Chong-Ren Wang; Shao-Ying Ke
Journal:  Mol Clin Oncol       Date:  2017-02-16

5.  PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.

Authors:  Loghman Salimzadeh; Nina Le Bert; Charles-A Dutertre; Upkar S Gill; Evan W Newell; Christian Frey; Magdeleine Hung; Nikolai Novikov; Simon Fletcher; Patrick Tf Kennedy; Antonio Bertoletti
Journal:  J Clin Invest       Date:  2018-08-07       Impact factor: 14.808

6.  High frequency, sustained T cell responses to PARV4 suggest viral persistence in vivo.

Authors:  Ruth Simmons; Colin Sharp; Stuart Sims; Henrik Kloverpris; Philip Goulder; Peter Simmonds; Paul Bowness; Paul Klenerman
Journal:  J Infect Dis       Date:  2011-05-15       Impact factor: 5.226

Review 7.  Long-term efficacy and safety of human papillomavirus vaccination.

Authors:  Rosa De Vincenzo; Carmine Conte; Caterina Ricci; Giovanni Scambia; Giovanni Capelli
Journal:  Int J Womens Health       Date:  2014-12-03

8.  Phenotypic analysis of peripheral B cell populations during Mycobacterium tuberculosis infection and disease.

Authors:  Willem J du Plessis; Alana Keyser; Gerhard Walzl; André G Loxton
Journal:  J Inflamm (Lond)       Date:  2016-07-29       Impact factor: 4.981

9.  Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.

Authors:  Lance Turtle; Filippo Tatullo; Tanushka Bali; Vasanthapuram Ravi; Mohammed Soni; Sajesh Chan; Savita Chib; Manjunatha M Venkataswamy; Prachi Fadnis; Mansour Yaïch; Stefan Fernandez; Paul Klenerman; Vijaya Satchidanandam; Tom Solomon
Journal:  PLoS Negl Trop Dis       Date:  2017-01-30

10.  Circulating and intrahepatic antiviral B cells are defective in hepatitis B.

Authors:  Alice R Burton; Laura J Pallett; Laura E McCoy; Kornelija Suveizdyte; Oliver E Amin; Leo Swadling; Elena Alberts; Brian R Davidson; Patrick Tf Kennedy; Upkar S Gill; Claudia Mauri; Paul A Blair; Nadege Pelletier; Mala K Maini
Journal:  J Clin Invest       Date:  2018-08-09       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.